Neopharma, Abu Dhabiâ€™s leading generic pharmaceutical manufacturing facility inaugurated its dedicated world class research and development centre in Musaffah on September 10th, 2012.
Dr B R Shetty – MD & CEO of Neopharma quoted the Hippocratic Oath as his guiding principle, â€œI will prescribe regimens for the good of my patients according to my ability and my judgments and never do harm to anyone.â€
Sharing his vision, Dr B R Shetty said, â€œThe future of healthcare can be assured by providing hi-tech pharmaceutical products and healthcare services to the UAE community and the neighboring regions.â€
While dedicating the Dr B R Shetty Research Centre to the community, Dr Shetty described the research centre as the cornerstone of innovation in pharmaceutical formulations, new drug delivery systems, nanotechnology and biological products for chronic or life threatening diseases.
Dr B R Shetty described the Research Centre as a pivotal hub for the development of novel drug delivery systems aimed at the treatment of Diabetes mellitus and Cancer. In this attempt neopharma has introduced modified release glyclazide(Glyka MR) & extended release metformin tablets (Neomet XR)for diabetic, Clarithromycin modified release(Resclar MR) tablets in antibiotic segment & Diclofenac sustained release tablets (Neoflam retard).
The research centre has collaborated with the Arkansas University for the development of microfiber nanotechnology for glucose sensors and nanotechnology based microchips for neurodegenerative disorders. In our collaboration with the biotech leader Biocon we have introduced novel nanotech product albumin bound paclitaxel for the treatment of breast cancer.
â€œNeopharma dedicates this world class facility to medical science.â€ Dr Shetty added.